Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
Part of paid clinical trials in Chandler, Arizona.
- Sponsor
- Biohaven Therapeutics Ltd.
- Study ID
- NCT06423781
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- BHV-7000 — DRUGBHV-7000 75 mg taken once daily
Study Details
The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).
Key Dates
- Start date
- Aug 1, 2024
- Status verified
- Mar 2026
- Primary completion
- Mar 18, 2026
- Completion
- Mar 18, 2026
Study Design
- Enrollment
- 233 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: BHV-7000
Primary Outcome Measure
Number of Participants With Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and AEs judged to be related to study medication [ Time Frame: Up to 104 weeks ]
Locations (66)
Find similar trials in Chandler, AZ
By condition
By specialty
Related Studies
- Study of Neuro-Cognitive Correlates of Pediatric Anxiety DisordersPHASE2 · Recruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderPHASE1 · Recruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- DBS for DepressionRecruiting · Baylor College of Medicine · Dallas, Texas
- Nitrous Oxide- Suicidal IdeationPHASE1 · Enrolling By Invitation · Washington University School of Medicine · St Louis, Missouri